Table 4.

Associations between disease-specific survival and clinicopathological characteristics in patients in TCGA using Cox regression.

Characteristics	Total (N)	HR (95% CI)	P -value	HR (95% CI)	P -value
		Univariate analysis	univariate analysis	multivariate analysis	multivariate analysis
T stage (T3 and T4 vs. T1 and T2)	345	2.089 (1.192–3.660)	0.010	1.052 (0.529–2.092)	0.884
N stage (N1 and N2 and N3 vs. N0)	334	1.807 (1.075–3.036)	0.025	0.802 (0.325–1.978)	0.632
M stage (M1 vs. M0)	333	2.438 (1.221–4.870)	0.012	0.888 (0.350–2.251)	0.802
Pathologic stage (Stage III and Stage IV vs. Stage I and Stage II)	331	2.146 (1.352–3.404)	0.001	1.703 (0.776–3.737)	0.184
Histologic grade (G3 vs. G1 and G2)	340	1.338 (0.862–2.078)	0.194
Histological type (diffuse type vs. tubular type)	129	1.115 (0.597–2.082)	0.734
Primary therapy outcome (CR vs. PD and SD and PR)	310	0.115 (0.072–0.184)	<0.001	0.108 (0.061–0.192)	<0.001
Residual tumor (R1 and R2 vs. R0)	314	5.142 (3.014–8.771)	<0.001	1.989 (1.036–3.816)	0.039
Age (>65 vs. ≤ 65)	346	1.211(0.797–1.840)	0.371
Race (Asian and Black or African American vs. White)	305	1.097 (0.656–1.836)	0.724
Gender (male vs. female)	349	1.573(0.985–2.514)	0.058	1.543 (0.874–2.722)	0.135
Anatomic neoplasm subdivision (fundus/body vs. antrum/distal)	253	0.850 (0.512–1.412)	0.531
Reflux history (yes vs. no)	208	0.598 (0.272–1.313)	0.200
Antireflux treatment (yes vs. no)	167	0.758 (0.380–1.511)	0.431
Barretts esophagus (yes vs. no)	201	0.974 (0.304–3.118)	0.964
TP53 status (Mut vs. WT)	346	1.007 (0.662–1.532)	0.974
PIK3CA status (Mut vs. WT)	346	0.815 (0.452–1.470)	0.497
MSC-AS1 (high vs. low)	349	1.455 (0.956–2.216)	0.080	1.368 (0.816–2.295)	0.235